Build vs Buy: Should Your DSO Develop In-House Smile Previews?

For a DSO with scale, building an in-house smile-preview tool looks tempting — own the technology, control the roadmap, avoid a per-location fee — but a believable photoreal AI is a hard, specialised engineering problem far from a dental group's core competency, and for almost every DSO the honest answer is buy. Build-versus-buy is a competency question, not a pride question. Here is the honest analysis.

Why is building tempting for a DSO?

Because at scale the recurring cost of a bought tool adds up, and owning the technology promises control. A DSO paying per location can look at the annual total and imagine building once and owning it forever, with a roadmap tuned to its own needs and no dependence on an outside vendor. The instinct is understandable: scale makes buying feel expensive and building feel like an asset. The question is whether that instinct survives contact with what building a believable photoreal preview actually requires — because the sticker price of a vendor is visible, and the true cost of building is not.

What does building actually require?

Far more than most groups expect — a photoreal preview is a specialised AI product, not a feature.

1. ML talent — scarce, expensive, hard to retain.
2. Model development — achieving believable realism is genuinely hard.
3. Ongoing maintenance — models drift; upkeep never stops.
4. Data and compliance — patient images demand serious care.
5. Support and iteration — a tool is a commitment, not a delivery.

Each of these is a standing cost and a distraction from running dental practices — the DSO's actual business.

How do build and buy really compare?

The recurring fee that made buying look expensive is usually small next to the true, ongoing cost of building and maintaining an AI product.

What does a DSO actually control by building?

Less than it hopes, and at a cost that rarely pays off — because control over a tool you must also maintain is a liability as much as an asset. Owning the technology means owning every bug, every model regression, every compliance obligation, and every future improvement, funded and staffed indefinitely. Meanwhile the realism bar keeps rising across the market, so an in-house tool that was competitive at launch needs continuous investment just to keep pace. A DSO that buys keeps the benefit of a specialist's ongoing improvement without carrying the engineering; that is a better kind of control — over outcomes, not code. Where the realism bar is heading is in the coming preview wars.

When might building make sense?

Only in the rare case where a group is so large that preview technology becomes strategic, and it is prepared to run a genuine software operation to match. A DSO with the scale, capital, and appetite to stand up a real AI team — and to treat the tool as a product with its own roadmap, support, and compliance function — could in principle build. But that is a decision to enter the software business alongside the dental one, with all the standing cost that implies. For the overwhelming majority of groups, that is neither the goal nor a good use of capital, and buying a specialist tool is the disciplined choice. The procurement lens for choosing a vendor is in the 12 procurement questions.

What's the honest recommendation?

Buy, for almost every DSO — and put the capital and attention into dentistry, patients, and growth, where the group's real advantage lies. A believable preview is a means to winning more cosmetic cases, not a technology a dental group needs to own; a good vendor delivers it faster, cheaper, and better-maintained than an in-house build, and keeps improving it as the market moves. Every preview, whoever builds it, should stay a visualization aid, not a guarantee — and the honest, credible version is easier to buy than to build. Focus the group on what only it can do, and let a specialist handle the AI. The wider category picture is in the state of AI in cosmetic dentistry.

What's the opportunity cost of building?

The dentistry, growth, and patient experience that the same capital and attention could have funded instead. Every engineer hired, every month spent tuning a model, and every compliance review absorbed by an in-house build is resource not spent on clinics, clinicians, and patients — the things a dental group actually competes on. Building an AI preview does not just cost money; it costs focus, pulling leadership into a software problem far from the group's strengths. For a DSO, the sharpest question is not “can we build this?” but “what do we give up by trying?” Measured that way, buying a specialist tool and keeping the group's energy on dentistry is almost always the higher-return choice — the build looks cheapest exactly when its hidden costs are counted least carefully.

Want the believable preview without building and maintaining an AI team? book a demo — qualified clinics get a trial set up personally after a short demo.